The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).
 
Lova Sun
Consulting or Advisory Role - Bayer; Genmab/Seagen; Genzyme; MJH Life Sciences; Regeneron
Research Funding - Blueprint Medicines (Inst); Erasca, Inc (Inst); IO Biotech (Inst); Seagen (Inst)
 
Roger B. Cohen
Honoraria - AstraZeneca
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Cantargia AB; Coherus Biosciences; Fstar Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); F-Star Biotechnology (Inst); Innate Pharma (Inst); Macrogenics (Inst); Xencor (Inst)
 
A. Dimitrios Dimitrios Colevas
Consulting or Advisory Role - Alpha BioCom; Beigene; ClearView Healthcare Partners; Deallus; Gilead Sciences; leidos biomedical research
Research Funding - Abbvie; AstraZeneca; Atara Biotherapeutics; BioNtech; BMS; CUE Biopharma; Cullinan Oncology; Exelixis; Experimental Therapeutics Clinical Trials Network (ETCTN); Forty Seven; Innate Pharma; Merck; NIH/NCI; NRG Oncology; Tessa Therapeutics